›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:CustomNext-Cancer®
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Konica MinoltaType:
Laboratory Developed Test
Related tests:
CustomNext-Cancer gives the flexibility to choose from up to 81 genes to accurately diagnose, treat, and manage patient’s cancer risks. All selected genes (excluding EPCAM and GREM1) are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for the following genes, if selected: PTEN (c.-1300 to c.-745), MLH1 (c.-337 to c.-194), and MSH2 (c.-318 to c.-65). For POLD1 and POLE, missense variants located outside of the exonuclease domains (codons 311-541 and 269-485, respectively) are not routinely reported. Testing to be consider if patient's complex personal and/or family history requires a unique panel of genes to assess (not found in an existing panel). CustomNext-Cancer can detect >99.9% of described mutations in the included genes, when present.
Gene:
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BLM (BLM RecQ Like Helicase)
See More ...
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BLM (BLM RecQ Like Helicase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1), CDK4 (Cyclin-dependent kinase 4), CDKN1B (Cyclin dependent kinase inhibitor 1B), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CHEK2 (Checkpoint kinase 2), CTNNA1 (Catenin Alpha 1), CTRC (Chymotrypsin C), EGFR (Epidermal growth factor receptor), EPCAM (Epithelial cell adhesion molecule), FLCN (Folliculin), HOXB13 (Homeobox B13), KIT (KIT proto-oncogene, receptor tyrosine kinase), MET (MET proto-oncogene, receptor tyrosine kinase), MITF (Melanocyte Inducing Transcription Factor), MLH1 (MutL homolog 1), MRE11A (MRE11 homolog, double strand break repair nuclease), MSH2 (MutS Homolog 2), MSH3 (MutS Homolog 3), MSH6 (MutS homolog 6), NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)), NF1 (Neurofibromin 1), NF2 (Neurofibromin 2), PALB2 (Partner and localizer of BRCA2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PMS2 (PMS1 protein homolog 2), POLD1 (DNA Polymerase Delta 1), POLE (DNA Polymerase Epsilon), PTEN (Phosphatase and tensin homolog), RAD50 (RAD50 Double Strand Break Repair Protein), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D), RET (Ret Proto-Oncogene), SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), SPINK1 (Serine peptidase inhibitor, kazal type 1), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53), TSC1 (TSC complex subunit 1), TSC2 (TSC complex subunit 2), VHL (von Hippel-Lindau tumor suppressor)
Method:
Next-Generation Sequencing (NGS)
